Clavis Pharma ASA has announced a delay in the start of a Phase 3 study of its new treatment for acute myeloid leukaemia (AML). Separately, the Norwegian oncology company said it has raised NOK 163 in a private share placement with investors. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals Regulation & Policy
